Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer.

Cancer 2008 Sep;113(6):1294-301

Department of Hematology-Oncology, Penn State Hershey Cancer Center, Penn State University/Hershey Medical Center, Hershey, Pennsylvania 17033, USA.

Background: Previous reports based on small patient numbers suggested that changes in serum HER-2/neu levels may predict response or lack of response to trastuzumab-based therapies in metastatic breast cancer (MBC). The objectives of this study were to pool data from 307 patients with MBC from 7 medical institutions to validate that the serum HER-2/neu profile predicts patient resistance to trastuzumab and to establish a clinically relevant cutoff.

Methods: This was an international, multicenter, retrospective analysis of individual pooled data from 307 patients with MBC who were treated with first-line trastuzumab-based therapy. Serum was collected at baseline and 30 to 120 days after the initiation of trastuzumab therapy. A serum HER-2/neu decrease >or=20% (receiver operating curve analysis) was defined as a significant HER-2/neu change.

Results: Of the 307 patients with MBC, 191 patients (62%) had a significant decline (>20%) in serum HER-2/neu and 116 patients (38%) did not. The objective response rate was 57% for patients who achieved this decline in serum HER-2/neu (>20%) compared with 28% for patients who did not. Patients who achieved this decline in serum HER-2/neu also had a significantly longer time to disease progression (320 days vs 180 days; P < .0001), longer duration of response (369 days vs 230 days; P = .008), and longer overall survival (898 days vs 593 days; P < .018).

Conclusions: In this pooled analysis of 307 patients with MBC, individuals who did not achieve a significant decline (>or=20%) in serum HER-2/neu levels had decreased benefit from trastuzumab-based therapy, and these patients should be considered for clinical trials evaluating additional HER-2/neu-targeted interventions.

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.23689DOI Listing
September 2008
37 Reads

Publication Analysis

Top Keywords

serum her-2/neu
32
patients mbc
16
307 patients
16
trastuzumab-based therapy
12
patients
11
serum
9
her-2/neu
8
her-2/neu levels
8
data 307
8
therapy patients
8
breast cancer
8
metastatic breast
8
decline serum
8
therapy serum
8
patients achieved
8
achieved decline
8
days
7
mbc
5
her-2/neu >20%
4
116 patients
4

References

(Supplied by CrossRef)
Circulating HER-2 extracellular domain and resistance to chemotherapy in advanced breast cancer
Colomer et al.
Clin Cancer Res. 2000

Similar Publications